

# Discovery of nonnucleoside inhibitors of polymerase from infectious pancreatic necrosis virus (IPNV)

Melissa Bello-Pérez<sup>1</sup>  
Alberto Falcó<sup>1</sup>  
Vicente Galiano<sup>2</sup>  
Julio Coll<sup>3</sup>  
Luis Perez<sup>1</sup>  
José Antonio Encinar<sup>1</sup>

<sup>1</sup>Molecular and Cell Biology Institute (IBMC), Miguel Hernández University (UMH), Elche, Spain; <sup>2</sup>Department of Physics and Computer Architecture, Miguel Hernández University (UMH), Elche, Spain; <sup>3</sup>Department of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain

**Introduction:** Infectious pancreatic necrosis virus (IPNV) causes serious losses in several fish species of commercial interest. IPNV is a non-enveloped double-stranded RNA virus with a genome consisting of two segments A and B. Segment B codes for the VP1 protein, a non-canonical RNA-dependent RNA polymerase that can be found both in its free form and linked to the end of genomic RNA, an essential enzyme for IPNV replication.

**Materials and methods:** We take advantage of the knowledge over the allosteric binding site described on the surface of the thumb domain of Hepatitis C virus (HCV) polymerase to design new non-nucleoside inhibitors against the IPNV VP1 polymerase.

**Results:** Molecular docking techniques have been used to screen a chemical library of 23,760 compounds over a defined cavity in the surface of the thumb domain. Additional ADMET (absorption, distribution, metabolism, excretion, and toxicity) filter criteria has been applied.

**Conclusion:** We select two sets of 9 and 50 inhibitor candidates against the polymerases of HCV and IPNV, respectively. Two non-toxic compounds have been tested in vitro with antiviral capacity against IPNV Sp and LWVRT60 strains in the low  $\mu\text{M}$  range with different activity depending on the IPNV strain used.

**Keywords:** IPNV, HCV, antiviral drugs, non-nucleoside inhibitors, RdRp, molecular docking

## Introduction

Since the discovery of the first vaccine against smallpox in 1796 by Edward Jenner, society has relied almost entirely on the development of new vaccines to battle viral diseases. However, the world's capacity for vaccine development is currently already falling behind the rate of emergence and reemergence of dangerous viral diseases. Indeed, viral diseases are particularly troublesome, because effective treatments against most of them are lacking. For instance, approximately half the short list of US Food and Drug Administration-approved antiviral drugs are aimed at HIV1 and those remaining target only six more viruses.<sup>1</sup> Furthermore, resistance to existing antimicrobials is emerging, along with new viral pathogens.<sup>2</sup> Consequently, urgent efforts are necessary to accelerate novel antiviral drug discovery. One such technology that has allowed for the in silico screening of large amounts of compounds for targeting specific sites within functionally significant proteins is the use of bioinformatic tools. Through the use of increasingly potent computational hardware systems combined with the ever-increasing availability of detailed information on the molecular structure of relevant proteins and extensive chemical libraries, significant advances have been made in both clinical and veterinary fields.<sup>3,4</sup>

Correspondence: José Antonio Encinar;  
Alberto Falcó  
Molecular and Cell Biology Institute,  
Edificio Torregaitán, Miguel Hernández  
University, Avenida de la Universidad,  
Eix 03202, Alicante, Spain  
Tel +34 9 665 8453  
Fax +34 96 665 8758  
Email jant.encinar@umh.es;  
alber.falco@umh.es

Infectious pancreatic necrosis virus (IPNV) was the first virus to be isolated from fish, and is now recognized as the known causative agent of IPN disease, which mainly affects cultured salmonids.<sup>5</sup> IPNV belongs to the family Birnaviridae and is a member of the genus *Aquabirnavirus*. IPNV is the prototype member of the genus *Aquabirnavirus* of the family Birnaviridae. The most characteristic macro- and histopathological symptoms of this disease are exophthalmia, skin hyperpigmentation, abdominal and pyloric petechial hemorrhages, erratic swimming, and necrosis of both the kidney and pancreas.<sup>5,6</sup>

Infection outbreaks by IPNV can cause high mortality in first-feeding fry and postsmolts,<sup>7,8</sup> consequently incurring high economic losses to the aquaculture industry.<sup>6,9,10</sup> The mortality rate is very variable (10%–90%) and affects youngest fish to a greater extent, reaching 45%, 35%, and 7% in 1-, 2-, and 4-month-old fish, respectively.<sup>11</sup> Interestingly, while currently unlisted in the Model Aquatic Health Code of the World Organization for Animal Health, the presence of IPNV is continuously being detected worldwide in both aquacultured<sup>12–17</sup> and wild fish, including several nonsalmonid species.<sup>15,17–19</sup> Apart from the fact that this virus is transmitted both vertically and horizontally,<sup>20,21</sup> fish that recover or are asymptotically infected often become carriers of the virus throughout their lives,<sup>11,22</sup> contributing to its broad spread. Unfortunately, there is no therapy for this disease, so current protective measures are aimed at avoiding and alleviating its incidence. Such approaches have included less stressful handling of animals, use of IPN-resistant fish lines, improved management procedures, and the use of vaccination programs. In any case, the spread of the virus has been shown to be unpredictable, and there is still room to improve the protection conferred by existing vaccines, such as reducing their cost and making them more suitable to all life stages.<sup>9</sup>

IPNV is an unenveloped virus with an icosahedral and single-shelled capsid (T=13 symmetry) of about 60 nm in diameter, which consists of two proteins (VP2 and VP3). Its linear dsRNA genome is bisegmented (segment A 3,097 nucleotide [nt], segment B, 2,784 nt), uncapped, and unpolyadenylated.<sup>10</sup> Segment A is bicistronic. Among its two open reading frames (ORFs), the largest one, ORF L, codes for the proteins VP2–4 as a 106-kDa polyprotein (NH<sub>2</sub>-pVP2-VP4-VP3-COOH) which is co-translationally cleaved by the viral protease VP4. The precursor pVP2 belongs to the major capsid protein VP2 (being most abundant overall),<sup>23</sup> of which VP3 is a minor capsid protein that complexes with the dsRNA genome.<sup>10</sup> In turn, the other segment-A ORF (ORF S) is not present in all isolates. ORF S overlaps the amino-terminal end of ORF L

and encodes VP5. VP5 is variable in size (3.3–17 kDa) and a nonstructural protein that is not essential for viral infectivity, but may contribute to the virulence of the strain by presumably triggering an antiapoptotic mechanism.<sup>24</sup> Segment B contains a single ORF that encodes the VP1 protein, which is a noncanonical RNA-dependent RNA polymerase (RdRp; 94 kDa). This protein, which can be found in its free form or indistinctly linked to the end of the genomic RNA (VPg),<sup>25</sup> lacks the hallmark catalytic GDD signature in the region corresponding to the presumptive motif VI of infectious bursal disease virus.<sup>26</sup> However, it presents a spatially rearranged LDD motif (residues 653–655 from Protein Data Bank [PDB] 2YI8).<sup>27</sup> VP1 also has enzymatic activity, such as that possessed by guanylyl and methyl transferase.<sup>28</sup>

Taking advantage of the knowledge obtained from previous studies on the allosteric binding site described on the surface of the thumb domain of hepatitis C virus (HCV) polymerase,<sup>29</sup> we herein explored a similar site in IPNV VP1 polymerase, allowing for the discovery of new antiviral drugs. This work describes the molecular docking results for a chemical library selected against a cavity site in the thumb domain of the RdRp of different IPNV strains, the successive filters applied for candidate compounds, and preliminary biological assays aimed at assessing antiviral capacity and specificity against two different IPNV strains for two of the selected candidates.

## Materials and methods

### Chemical compounds for antiviral assays

The compounds with the PubChem IDs 3274414 and 39834288 were purchased from the chemical supplier Ambinter (supplier references Amb10836885 and Amb674545, respectively) (Ambinter c/o Greenpharma Orléans, France).

### Protein structure for IPNV RNA-dependent RNA-polymerase VP1 and chemical libraries

To date, five resolved structures have been deposited in the PDB for the VP1 protein of the Jasper strain of IPNV (UniProt code P22173): 2YI8, 2YI9, 2YIA, 2YIB, and 3ZED.<sup>30,31</sup> However, no structures of this protein are yet deposited for the Sp (UniProt code P22174) or LWVRT60 (UniProt code A0A1B2AQF1) strains. Therefore, three-dimensional (3-D) structural models of the VP1 protein from both strains were generated by homology modeling in automated mode, using the 2YIB structure as a template.<sup>32</sup> Briefly, a template search with BLAST and HHblits was performed against the Swiss-Model Template Library (SMTL; last update

December 6, 2017, last included PDB release December 1, 2017). The target sequence was searched with BLAST<sup>33</sup> against the primary amino-acid sequence contained in the SMTL. A total of 28–30 templates were found in each case. An initial HHblits profile was built using the procedure outlined in Remmert et al,<sup>34</sup> followed by one iteration of HHblits against NR20. The profile obtained was then searched against all profiles of the SMTL. A total of 140–163 templates were found in each case. For each template identified, its quality was predicted from features of the target-template alignment. Templates of the highest quality were then selected for model building. Models were built based on the target-template alignment using ProMod II. Coordinates conserved between the target and the template were copied from the template to the model. Insertions and deletions were remodeled using a fragment library. Side chains were then rebuilt. Finally, the geometry of the resulting model was regularized using a force field. In cases where loop modeling with ProMod II<sup>35</sup> did not yield satisfactory results, an alternative model was built with Modeller.<sup>36</sup> For these molecular docking studies, amino-acid sequences 31–36 and 122–157 were electronically removed in both models and template. Structures 2BRK and 2BRL of HCV NS5 RdRp from Di Marco et al<sup>29</sup> were used additionally, thereby employing nine structures for overall structural refinement. Visualization of the structures and preparation of the figures were carried out with PyMol 2.0 software.

For these experiments, a chemical library of 23,764 compounds was built using the option available at the PubChem site (<https://pubchem.ncbi.nlm.nih.gov/search/search.cgi>; in the “Identity/similarity” section) for searching structurally similar compounds to a given template. In our case, the structures of compounds 1 (PubChem ID 4369534) and 2 (PubChem ID 4369535), which were described to interact with the polymerase of HCV and to inhibit its activity,<sup>29</sup> were used as query templates. Compounds were subsequently searched with at least 70% structural identity, thus generating a chemical library to be tested in molecular docking experiments. The PubChem web application used herein to allowed for the 3-D chemical structure of all compounds retrieved to be downloaded as spatial data files.

## Molecular docking procedures

Before carrying out molecular docking experiments, PDBQT files of both the protein (receptor) and the ligands of our chemical library were calculated.<sup>37,38</sup> Next, the five structures and two models of VP1 proteins were subjected to a geometric optimization process using the repair function of the FoldX algorithm.<sup>39</sup> Molecular docking experiments were

performed using AutoDock Vina software version 1.1.2<sup>40</sup> and targeted to a grid with dimensions of 24×24×24 points centered around the cavity generated by the amino acids Glu557, Asn580, Ans624, Pro625, and Pro550 of HCV NS5 RdRp and likewise around the amino acids Trp500, Arg503, Pro495, Val494, Leu492, Leu392, Ala396, and His428 of the VP1 protein of IPNV. AutoDock Vina was set up on a lusitania2.cenits.es Linux cluster (Research, Technological Innovation, and Supercomputing Center of Extremadura, Cáceres, Spain). AutoDock Vina generates for each tested ligand a conformer docked to the binding site in the protein and calculates the Gibbs free-energy variation of the binding process. Compounds with lower  $\Delta G$  (kcal/mol) outperform a first-screening filter as potential candidates for inhibitors.

## Calculation of pharmacokinetic parameters and potential toxicity of inhibitor candidates

Physicochemical parameters for the best-docked compounds were calculated as described previously<sup>37,38</sup> using DataWarrior version 4.7.2.<sup>41</sup> ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties were calculated with the AdmetSAR web application<sup>42</sup> and DataWarrior.<sup>41</sup> The same applications were used to calculate these parameters for the drugs included in the DrugBank database,<sup>43</sup> and they are available at the website <http://dockingfiles.umh.es/drugbank/DrugBanklist.asp>.

## Cell culture and viral strains

The Chinook salmon-embryo cell line CHSE214 was purchased from the (European Collection of Authenticated Cell Cultures, Public Health England, Salisbury, UK) (91041114). It was maintained at 20°C in a 5% CO<sub>2</sub> atmosphere in Roswell Park Memorial Institute (RPMI) 1640 (Dutch modification) medium containing 10% FBS (Sigma-Aldrich, St Louis, MO, USA), 2 mM glutamine (Thermo Fisher Scientific, Waltham, MA, USA) and 50 µg/mL gentamicin (Thermo Fisher Scientific). Both Sp and LWVRT60 strains of IPNV were grown in CHSE214 cells at 14°C. When cytopathic effects were widespread, supernatants from infected cell cultures were clarified by centrifugation, filtered (0.22 µm), and stored in aliquots at –80°C. Virus titers were determined by end-point dilution in confluent CHSE214-cell monolayers grown in 96-well plates at 14°C in infection medium (ie, growth medium supplemented with 2% instead of 10% FBS). The Reed–Muench method<sup>44</sup> was used to calculate 50% tissue-culture infective dose (TCID<sub>50</sub>)/mL. Average TCID<sub>50</sub>/mL (and SD) for each batch was obtained from three different titrations.

## Cytotoxicity assays

The potential toxicity of selected compounds on CHSE cells was analyzed by measuring changes in cell viability with MTT (Sigma-Aldrich) assays. Briefly, confluent cell monolayers in 96-well plates were treated with different concentrations of each type of compound in infection media for 24 hours (100  $\mu$ L/well). Then, 0.5 mg/mL MTT from tenfold-concentrated stocks in PBS (stored at  $-20^{\circ}\text{C}$ ) in fresh media (100  $\mu$ L/well) was used to replace treatments. MTT solutions were incubated with cells under the same conditions for an additional 4 hours. Finally, media were carefully removed and the colored formazan product dissolved in 100  $\mu$ L dimethyl sulfoxide (DMSO; Merck, Kenilworth, NJ, USA) and measured at 570 nm vs reference absorbance at 620 nm with a SpectroStar Omega absorbance microplate reader (BMG LabTech, Ortenberg, Germany). OD is expressed in percentages relative to the control group consisting of untreated cells. Additional controls included corresponding compounds and solvents (DMSO for the PubChem 3274414 compound and DMSO:acetone 1:1 for the PubChem 39834288 compound up to a maximum final concentration of 0.5% v:v) at an equivalent concentration to that used at each compound concentration tested at 1, 5, 10, 20, and 50  $\mu$ M. Cell viability was calculated by the formula:  $100 \times (\text{treated-cell absorbance} / \text{control-cell absorbance})$ . All experiments were performed in triplicate, and results are shown as mean with SD calculated from three different experiments.

## Antiviral assays

To test the influence of the selected compounds on IPNV infectivity, IPNV was added at a 0.01 multiplicity of infection in 100  $\mu$ L RPMI 1640 (Dutch modification) medium supplemented with 2% FBS (infection medium) to confluent CHSE-cell monolayers grown in 96-well plates and incubated for 2 hours at  $4^{\circ}\text{C}$  (adsorption period). Then, infected cell monolayers were washed twice with PBS and compounds (PubChem ID 3274414 was dissolved in DMSO and PubChem ID 39834288 in DMSO:acetone 1:1) were added to corresponding wells in 100  $\mu$ L infection medium at different concentrations of 1, 5, 10, 20, and 50  $\mu$ M. The final concentration of organic solvent never exceeded 0.5% (v:v). Infected cells were further incubated with the treatments for 24 hours at  $14^{\circ}\text{C}$ . After incubation, cells were collected for quantification of the virus by reverse-transcription quantitative polymerase chain reaction (RT-qPCR). In parallel and as a control for each concentration of compound used, infected cells were also treated with the corresponding solvents at a concentration equivalent to each concentration of compound used. Positive and negative infection controls were also included.

All conditions were performed in tetraplicate (RT-qPCR was performed by pooling the cells of all replicates).

## RNA isolation, cDNA synthesis, and RT-qPCR assays

Levels of each IPNV strain replicating in infected CHSE cells were evaluated by determining their content in viral transcripts. Therefore, RT-qPCR was performed on cDNA from CHSE-cell RNA previously used in the antiviral assays. Therein, RNA from the aforementioned collected cells was isolated using an E.Z.N.A.<sup>®</sup> Total RNA kit (Omega Biotek, Norcross, GA, USA) following the manufacturer's guidelines. RNA concentration was assessed using a NanoDrop 1,000 spectrophotometer (Thermo Fisher Scientific) by measuring absorbance at 260 nm. Samples were stored at  $-80^{\circ}\text{C}$  until use.

In order to obtain cDNA reverse transcriptase (Moloney murine leukemia virus; Thermo Fisher Scientific), 1  $\mu$ g RNA from each sample was used, as previously described.<sup>45</sup> RT-qPCR reactions were carried out using the ABI 7300 Real-Time PCR System (Thermo Fisher Scientific) with SYBR<sup>®</sup> Green Master Mix PowerUp SYBR Green Master Mix (Thermo Fisher Scientific). The total volume of each reaction was 20  $\mu$ L and included 2  $\mu$ L cDNA, 900 nM each primer, and 10  $\mu$ L SYBR green PCR master mix. Nontemplate controls were performed for each gene analysis. Cycling conditions were  $95^{\circ}\text{C}$  for 10 minutes, followed by 40 cycles of 1 minute at  $65^{\circ}\text{C}$ , 15 seconds at  $95^{\circ}\text{C}$ , and finally an extension of 1 minute at  $60^{\circ}\text{C}$  and 15 seconds at  $95^{\circ}\text{C}$ . Results were obtained by normalizing the expression of the target gene respective to that of the endogenous reference using a variation of Livak and Schmittgen's method<sup>46</sup> by the formula  $2^{C_{\text{ref}} - C_{\text{target}}}$ . The endogenous gene used in this study was elongation *ef1a*. Primers used are shown in Table 1. All reactions were performed in duplicate. Results are presented as percentages of inhibition of IPNV infectivity relative to values obtained by an equivalent amount of corresponding solvent, and correspond to means with SD calculated from four different experiments.

## Results and discussion

### Exploring allosteric binding-site cavity from IPNVVPI protein

Di Marco et al<sup>29</sup> reported the crystal structure of HCV RdRp (genotype 1b, strain BK) in a complex with two nonnucleoside inhibitors occupying a cavity (Figure 1A) that appeared in the thumb domain for deletion mutants lacking the 55 amino acids at the C-terminus ( $\Delta$ C55). Both compounds inhibited not only the purified full-length and truncated C-terminal  $\Delta$ C55 enzyme in a low-nanomolar range but also the replicon

**Table 1** Primers used in this study


Organism <sup>a</sup>	Gene/segment <sup>b</sup>	Sequence (5'–3')	Accession <sup>c</sup>	Reference(s) <sup>d</sup>
<i>Salmo salar</i>	<i>efl a</i>	Fw: GCCCCTCCAGGATGTCTAC Rv: CACGGCCCCACAGTACTG	BG933897	47
IPNV Sp	<i>segA</i>	Fw: TCTCCCGGGCAGTTCAAGT Rv: CGGTTTCACGATGGGTTGTT	AJ622822	48, 49
IPNV LWVRT60	<i>segB</i>	Fw: TCGAGAACAAGACCCTTGCC Rv: GACATGTGTTTTGCTGCGGT	KU609619	This study

**Notes:** <sup>a</sup>Organism (scientific name) or IPNV strain; <sup>b</sup>target-organism gene or IPNV-strain genome segment; <sup>c</sup>GenBank accession number of target sequences; <sup>d</sup>studies in which these primers have been used previously.

**Abbreviations:** IPNV, infectious pancreatic necrosis virus; Fw, forward; Rv, reverse.

system, although with minor affinity (15–30 times lower). This cavity is not accessible in the crystal structure of the full-length protein, and arises after displacement of the  $\alpha$ -helix, which implies that the interaction between thumb and fingers

is weak enough to allow for a slightly open structure of the polymerase.<sup>29</sup> This observation suggests that a priori this domain in IPNV VP1 polymerase might also be displaced similarly by the interaction of molecules with its corresponding

**Figure 1** Cavity for the allosteric binding site in the thumb domain of viral RdRp.

**Notes:** (A) Allosteric binding site around the amino-acid side chains of Leu392, Ala395, Thr399, Ile424, Leu425, His428, and Phe429 of crystal structure with the PDB number 2BRK, also including the cocrystallized PubChem ID inhibitor 4369534<sup>29</sup> in yellow, the same compound docked in light green, and the best-docked PubChem ID 23515664 compound in pink. (B) Structural features of IPNV VP1 RdRp (2Y18) as ribbon representation (1), as electrostatic surface potential with the amino acid sequence 122–157 and 31–36 as ribbon (2), detail of the cavity near the Arg551 (3), and electrostatic surface potential of the deletion mutant  $\Delta$ 122–157 and  $\Delta$ 31–36 used for molecular docking purposes (4). (C) Chemical structure of compounds experimentally tested in this work. PubChem ID numbers included. (D) Secondary structure of the protein region that forms the cavity explored in molecular docking experiments. The right side shows the sequence alignment for this region of the protein in IPNV Jasper, Sp, and LWVRT60 strains. Blue and orange boxes indicate the amino-acid sequences for the left side.

**Abbreviations:** RdRp, RNA-dependent RNA polymerase; PDB, Protein Data Bank; HCV, hepatitis C virus; IPNV, infectious pancreatic necrosis virus.

homologous cavity. Therefore, potential antiviral drugs against IPNV could be designed against that cavity without generating deletion mutants.

Five high-resolution structures are known for the VP1 polymerase of the Jasper strain of IPNV. It can be observed that unlike HCV polymerase, there is a partially accessible cavity even if residues 122–157 of the thumb domain in HCV polymerase are present (Figure 1B). This cavity becomes more evident for the same structure when amino acids 122–157 are electronically removed (Figure 1B). Although no high-resolution structures of the VP1 protein are available for the Sp and LWVRT60 IPNV strains, those available in our laboratory show high sequence identity (88.7%–99.5%) with Jasper VP1. This is especially true for the three domains involved in the definition of the cavity (Figure 1D). For this reason, homology modeling of the VP1 protein using the structures of the Jasper strain as a template was carried out.<sup>38</sup> In both the available structures and resulting models, the amino-acid sequences 122–157 and 31–36 were electronically deleted and molecular docking experiments carried out on the resulting structures.

### Analysis of compounds docked to cavity on surface of thumb domain

Initially, an *in silico* screening of our chemical library was carried out on HCV polymerase, in order to check the predictive capacity of AutoDock Vina with the compound

cocrystallized by Di Marco et al, define thresholds for the variation of Gibbs free energy ( $\Delta G$ , kcal/mol) in the screening process, and find compounds with smaller  $\Delta G$  values, and then potentially higher affinity, than those tested by Di Marco et al.<sup>29</sup> Collectively, such data would allow for a targeted approach in the design of potential inhibitors of the IPNV VP1 protein, as was the main objective of this study.

Figure 1A depicts compound one in yellow (PubChem 4369534), present in the crystal structure with the PDB number 2BRK.<sup>29</sup> The same compound highlighted in light green is shown superimposed after molecular docking calculations ( $\Delta G = -8.75$  kcal/mol). Docked and experimental conformation of 4369534 compound had an root-mean-square deviation of 5.141 Å. Finally, one of the optimal compounds with respect to binding was calculated from our chemical library (PubChem 23515664), and is depicted in pink. Docking calculations for compound 2 (PubChem 4369535) also predicted a conformer interacting in such a cavity, in agreement with that obtained through cocrystallization-derived structures<sup>29</sup> (not shown) and with a similar  $\Delta G$  value ( $-8.60$  kcal/mol). After analysis of the docking data for our chemical library against HCV structures (2BRK $\Delta$ 31–36,  $\Delta$ 122–157 and 2BRL $\Delta$ 31–36,  $\Delta$ 122–157) we found 200 compounds (not shown) with  $\Delta G$  values  $\leq -9.0$  kcal/mol (the  $\Delta G$  value chosen as threshold based on previous calculated results for Di Marco et al's active compounds; Figure 2), and among





Figure 2 (Continued)



**Figure 2** Comparison of Gibbs free energy ( $\Delta G$ ) variation for selected compounds based on molecular docking.

**Notes:** (A) Optimal compounds selected (minor  $\Delta G$ ) against HCV NS5B RdRp and their  $\Delta G$  against IPNV VPI polymerase of Sp, Jasper, and LWVRT60 strains. (B, C) Optimal compounds selected against each of the three strains of IPNV and their  $\Delta G$  values with respect to the remaining strains and HCV. PubChem ID number is indicated in black below each value, except for the inhibitors described by Di Marco et al<sup>29</sup> (red) and the two compounds experimentally tested in this study (blue).

**Abbreviations:** HCV, hepatitis C virus; RdRp, RNA-dependent RNA polymerase; IPNV, infectious pancreatic necrosis virus.

these 26 compounds with  $\Delta G$  values  $\leq -9.5$  kcal/mol. Calculated  $\Delta G$  values for compounds that primarily bind to hydrophobic sites are greater than expected when the binding site is more hydrophilic. As a consequence, in these cases the  $K^i$  calculated from the value of  $\Delta G$  ( $K^i = \exp^{\Delta G/RT}$ )<sup>38</sup> did not

correspond to the experimental values in the subnanomolar range for compounds 1 and 2.

Of those 26 compounds with the lowest  $\Delta G$  values, 17 were discarded, as their ADMET profiles were not optimal. In this sense, the range of optimal values was slightly

varied for different parameters with respect to other research by our group.<sup>37,38</sup> Briefly, different parameters of the ADMET profile were analyzed (Figure 3) for both approved and experimental drugs included in the DrugBank

database<sup>43</sup> (these data are available at the website <http://dockingfiles.umh.es/drugbank/DrugBanklist.asp>). Eight of the nine parameters analyzed in Figure 3 show a Gaussian distribution in a frequency where 80%–90% of the





Figure 3 (Continued)



**Figure 3** Analysis of physicochemical parameters of drugs included in the DrugBank database.

**Notes:** Distribution of molecular weight (A), calculated LogP (B), drug score (C), drug likeness (D), HBD (E), HBA (F), topological polar surface area (G), and violations of Lipinski et al's<sup>50</sup> rule of five (H) drugs included in the DrugBank database.<sup>43</sup> Each panel includes a curve indicating Gaussian distribution of frequency of parameter analyzed.

**Abbreviations:** LogP, logarithm of partition coefficient; HBD, hydrogen-bond donor; HBA, hydrogen-bond acceptor; TPSA, topological polar surface area; Ro5, rule of five.

values of these parameters varied by molecular weight, calculated logarithm of partition coefficient, drug score, drug likeness, H-bond acceptor, hydrogen (H)-bond donor, and topological polar surface area. In this manner, it can be observed that a high percentage of these drugs showed values in several parameters that are far from standard as was especially evident for drug score, drug likeness, and topological polar surface area. Moreover, up to 21% of these drugs present more than one violation of Lipinski's rules.<sup>50</sup> According to these data, the extreme values of these Gaussian distributions will be taken into account to be used as a screening filter for potential antiviral drugs

against IPNV. Even up to 3 violations of Lipinski's rules were admitted (See Tables 2, 4 and 6).

In Figure 2A, calculated  $\Delta G$  values for selected compounds are compared to compounds 1 (4369534) and 2 (4369535)<sup>29</sup> for not only HCV but also all three IPNV strains. As expected, both compounds showed an  $\Delta G$  value of almost 2 kcal/mol higher for all the IPNV strains, as they were not designed for targeting their polymerases. This occurred similarly with the nine compounds selected against HCV (Figure 2A). These data reflect the differences in the volume of the cavity and in the sequence of amino acids that define it between HCV and IPNV.

**Table 2** Calculated physicochemical parameters for selected compounds against HCV NS5B RdRp based on molecular docking analysis

Compounds	Clusters	TPSA (Å <sup>2</sup> )	cLogS	MW	cLogP	HBA	HBD	Ro5 violations	Drug likeness	Drug score
<b>4369534</b>	1	71.77	-4.539	446.545	4.3728	6	1	0	-0.91217	0.212791182
<b>4369535</b>	1	65.78	-4.711	501.669	4.1731	6	1	1	2.8068	0.290325582
23152308	2	61.08	-6.189	532.686	7.695	6	1	2	1.9041	0.129071139
23515664	3	84.22	-5.904	467.567	5.5929	6	2	1	-1.0435	0.219641626
23515666	3	70.14	-7.345	465.474	5.868	5	1	1	-8.1071	0.141128842
23515667	3	64.35	-7.269	466.458	6.0954	5	1	1	-8.6848	0.136743667
23515710	3	84.22	-5.634	453.54	5.1385	6	2	1	0.17978	0.311684528
23515871	3	127.31	-5.795	468.512	4.0863	8	3	0	-0.002769	0.335480502
23515908	3	84.22	-5.522	439.514	4.7084	6	2	0	-0.0094093	0.338105422
78298451	4	156.22	-6.052	605.649	2.8246	11	2	2	1.045	0.316872425
78400566	5	115.46	-6.249	538.602	4.52	9	2	1	-8.1363	0.102868689

**Notes:** Compounds in bold are inhibitors of the HCV polymerase experimentally tested.<sup>29</sup> Compound names obtained from PubChem. Each cluster groups compounds with structures with up to 80% structural similarity.<sup>50</sup>

**Abbreviations:** HCV, hepatitis C virus; RdRp, RNA-dependent RNA polymerase; TPSA, topological polar surface area; cLogS, calculated logarithm of solubility; MW, molecular weight; cLogP, calculated logarithm of partition coefficient; HBA, hydrogen-bond acceptor; HBD, hydrogen-bond donor; Ro5, rule of five.

**Table 3** Predicted molecular pharmacokinetic properties of selected compounds against HCV NSSB RdRp

Compounds		ADME													
BBB	HIA	Caco2 permeability (LogP <sub>app</sub> , cm/s)	Caco2 permeability (LogP <sub>app</sub> , cm/s)	Pgp substrate inhibitor	Pgp substrate inhibitor	Pgp substrate inhibitor	CYP450 2c9 substrate	CYP450 2c9 substrate	CYP450 2c9 substrate	CYP450 3a4 substrate	CYP450 2d6 inhibitor	CYP450 2c9 inhibitor	CYP450 2c19 inhibitor	CYP450 3a4 inhibitor	CYP ROCT IP
+	+	0.5784	0.5784	+	+	-	-	-	-	-	-	-	-	-	Low
+	+	0.8928	0.8928	+	+	-	-	-	-	-	-	-	-	-	Low
+	+	1.4709	1.4709	+	+	-	-	-	-	-	-	-	-	-	High
+	+	0.468	0.468	+	+	-	-	-	-	-	-	-	-	-	High
+	+	0.9467	0.9467	-	-	-	-	-	-	-	-	-	-	-	High
+	+	0.9213	0.9213	-	-	-	-	-	-	-	-	-	-	-	High
+	+	0.4514	0.4514	+	+	-	-	-	-	-	-	-	-	-	High
+	+	0.3009	0.3009	-	-	-	-	-	-	-	-	-	-	-	Low
+	+	0.4909	0.4909	+	+	-	-	-	-	-	-	-	-	-	High
-	+	0.0684	0.0684	+	+	-	-	-	-	-	-	-	-	-	Low
+	+	0.2807	0.2807	+	+	-	-	-	-	-	-	-	-	-	Low

**Notes:** Compounds in bold are inhibitors of the HCV polymerase experimentally tested.<sup>29</sup> All parameters calculated using <http://immd.ecust.edu.cn:8000/predict/site>.<sup>42</sup>  
**Abbreviations:** HCV, hepatitis C virus; RdRp, RNA-dependent RNA polymerase; ADME, absorption, distribution, metabolism, elimination; BBB, blood-brain barrier; HIA, human intestinal absorption; P<sub>app</sub>, apparent permeability coefficient; IP, inhibitory promiscuity; ROCT, renal organic cation transporter.

**Table 4** Predicted toxicity assessment of selected compounds against HCV NSSB RdRp

Toxicity profile	4369534	4369535	23152308	23515664	23515666	23515667	23515710	23515871	23515908	78298451	78400566
Mutagenic <sup>a</sup>	None										
Tumorigenic <sup>c</sup>	None										
RE <sup>a</sup>	High										
Irritant <sup>c</sup>	None										
HERG inhibition I <sup>b</sup>	Weak										
HERG inhibition II <sup>b</sup>	-	-	+	+	+	+	+	+	+	+	+
Ames toxicity <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-
Carcinogens <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-
FT (pLC <sub>50</sub> , mg/L) <sup>b</sup>	High, 1.3334	High, 1.2745	High, 1.0762	High, 1.5414	High, 1.037	High, 0.6405	High, 1.4738	High, 1.3289	High, 1.4462	High, 1.1014	High, 1.174
TPT (pIGC <sub>50</sub> , µg/L) <sup>b</sup>	High, 0.388	High, 0.5375	High, 0.4226	High, 0.3794	High, 0.6917	High, 0.9935	High, 0.3714	Low, 0.3363	High, 0.3439	High, 0.4889	High, 0.4499
Honeybee toxicity <sup>b</sup>	Low										
Biodegradation <sup>b</sup>	-	-	-	-	-	-	-	-	-	-	-
Acute oral toxicity <sup>b</sup>	III										
Carcinogenicity (three-class) <sup>b</sup>	Not required										
RAT (LD <sub>50</sub> , mol/kg) <sup>b</sup>	2.2189	2.696	2.701	2.2834	2.8229	2.6911	2.3196	2.5033	2.3824	2.7072	2.4479

**Notes:** Toxicity data was expressed as the negative logarithm of 50% growth inhibitory concentration (pIGC50). The value of LD50 for a substance is the dose required to kill half the members of a tested population after a specified test duration. Compound names from PubChem. <sup>a</sup>Calculated using DataWarrior<sup>41</sup> version 4.7.2; <sup>b</sup>calculated using <http://immd.ecust.edu.cn:8000/predict/site>.<sup>42</sup>  
**Abbreviations:** HCV, hepatitis C virus; RdRp, RNA-dependent RNA polymerase; RE, reproductive effectiveness; FT, fish toxicity; LC<sub>50</sub>, lethal concentration at 50%; TPT, *Tetrahymena pyriformis* toxicity; RAT, rat acute toxicity.

**Table 5** Calculated physicochemical parameters for selected compounds against IPNV VPI RdRp based on molecular docking analysis

Compounds	Clusters	TPSA (Å <sup>2</sup> )	cLogS	MW	cLogP	HBA	HBD	Ro5 violations	Drug likeness	Drug score
10280893	1	163.14	-3.464	552.641	2.285	12	4	2	-1.0971	0.371867727
18537979	1	166.38	-2.435	553.629	1.2329	13	4	2	1.4422	0.579621051
20739933	2	96.11	-7.217	480.566	4.8776	7	3	0	1.5843	0.239607744
58953872	2	96.11	-7.487	494.593	5.2196	7	3	1	1.5843	0.269858554
23152686	3	109.24	-6.054	534.614	6.0037	8	3	2	-0.32674	0.118698802
23152929	3	71.94	-6.041	490.605	6.689	6	2	1	-0.27206	0.119642868
23152934	3	61.08	-5.704	504.632	6.8218	6	1	2	0.72092	0.141347709
66795702	3	71.94	-6.112	504.632	6.9757	6	2	2	0.98293	0.134739208
24054864	4	86.21	-7.442	489.53	5.8066	7	1	1	1.7705	0.120414447
24163747	5	86.21	-6.787	479.535	5.2461	7	1	1	-1.2712	0.117405963
24967621	6	80.15	-6.17	481.594	4.6727	6	2	0	2.0585	0.358603377
71452538	6	58.22	-5.759	469.627	5.4654	5	1	1	1.9467	0.340567283
71456057	6	67.01	-6.488	491.633	5.484	5	2	1	1.6836	0.287416263
71457852	6	58.22	-5.489	455.6	5.1234	5	1	1	3.955	0.40928884
71457853	6	80.15	-6.514	495.621	5.0166	6	2	1	2.1942	0.317209639
71461490	6	79.9	-5.717	492.621	4.5371	6	2	0	1.6836	0.375823294
71463215	6	80.15	-6.538	495.621	5.0706	6	2	1	1.1437	0.290088161
24999215	7	93.45	-4.726	495.577	4.3431	7	2	0	3.6601	0.485783392
25204841	8	47.09	-6.513	448.568	5.4178	5	0	1	1.453	0.307833286
25358606	9	76.9	-5.43	482.538	3.7813	8	0	0	7.4652	0.479134432
3012662	10	131.39	-7.516	669.78	6.2485	10	3	2	1.3775	0.164791551
3012705	10	131.39	-7.055	617.704	4.7679	10	3	1	1.4271	0.2342033
5743088	10	115.46	-6.249	538.602	4.52	9	2	1	-8.1363	0.102868689
3274414	11	98.74	-6.306	472.539	5.3692	5	1	1	-1.5436	0.158941452
39834288	12	86.69	-3.251	320.375	1.8408	5	0	0	4.6379	0.855850841
42170436	13	126.05	-6.307	469.5	3.6969	9	3	0	0.35709	0.273696271
42228107	14	119.34	-5.288	477.483	3.0042	10	2	0	4.5258	0.523365319
44815258	15	120.35	-3.385	588.666	4.4852	10	2	1	0.49074	0.379468126
44816797	15	124.26	-3.804	584.634	5.1162	10	2	2	0.94695	0.353975046
490824	16	109.47	-7.253	551.645	5.2766	9	2	2	-1.7804	0.151308017
5273375	17	143	-5.987	605.697	4.7129	11	4	2	-0.3175	0.216436088
5276097	18	77.24	-7.315	489.573	6.4855	6	1	1	-4.5325	0.124874159
5276122	19	97.55	-7.057	574.679	6.3309	8	1	2	-0.29605	0.123835809
59237129	20	94.56	-4.486	438.533	3.7911	7	4	0	-0.55945	0.411185665
59604390	21	63.15	-5.468	462.551	4.6925	6	1	0	6.4596	0.15810365
59605198	21	63.15	-5.782	480.542	4.7933	6	1	0	5.1196	0.142503799
59784249	22	121.03	-6.033	518.575	3.0633	9	4	1	4.9822	0.425742108
59785406	22	121.03	-5.618	490.522	2.4327	9	4	0	3.8764	0.492489568
59784414	23	110.17	-7.855	530.586	2.7996	9	3	1	4.7368	0.351433623
59785246	24	110.17	-5.611	504.549	2.6026	9	3	1	6.019	0.480801976
9959508	25	139.29	-5.4	561.527	3.4903	11	3	2	-2.4649	0.227350159
69978228	25	189.61	-4.132	582.619	2.1062	13	5	2	3.1151	0.515992208
70114340	26	162.36	-2.901	504.553	2.1538	10	5	1	3.9231	0.676691765
71194466	27	109	-7.502	489.534	4.1577	8	3	0	3.3098	0.343673151
71452539	28	76.24	-5.85	485.626	4.3657	6	2	0	0.56667	0.339399549
72561223	29	110.17	-4.503	510.596	2.0128	9	3	1	5.1802	0.579372462
74318036	30	112.47	-6.421	572.751	4.478	9	5	1	2.2466	0.14379847
76259895	31	96.76	-6.713	483.57	3.1192	8	3	0	4.4867	0.414597223
77236156	32	141.84	-4.624	584.634	3.3632	10	4	1	-0.75495	0.305553124

**Notes:** Compound names obtained from PubChem. Each cluster groups compounds with structures with up to 80% structural similarity.<sup>50</sup>

**Abbreviations:** IPNV, infectious pancreatic necrosis virus; RdRp, RNA-dependent RNA polymerase; TPSA, topological polar surface area; cLogS, calculated logarithm of solubility; MW, molecular weight; cLogP, calculated logarithm of partition coefficient; HBA, hydrogen-bond acceptor; HBD, hydrogen-bond donor; Ro5, rule of five.

**Table 6** Predicted molecular pharmacokinetic properties of selected compounds against IPNV VPI RdRp

Compounds	ADME	BBB	HIA	Caco2 permeability	Caco2 permeability (LogP <sub>app</sub> , cm/s)	Pgp substrate	Pgp inhibitor I	Pgp inhibitor II	CYP450 substrate	CYP450 2c9 substrate	CYP450 2d6 substrate	CYP450 3a4 substrate	CYP450 1a2 inhibitor	CYP450 2c9 inhibitor	CYP450 2d6 inhibitor	CYP450 2c19 inhibitor	CYP450 3a4 inhibitor	CYP450 IP	CYP ROCT
490824	+	+	-	-	0.5656	+	-	-	-	-	-	-	-	-	-	-	-	Low	-
3012662	-	+	-	-	0.0447	+	+	-	-	-	-	-	-	-	-	-	-	Low	-
3012705	-	+	-	-	0.0648	+	+	-	-	-	-	-	-	-	-	-	-	Low	-
3274414	+	+	-	-	1.5102	-	+	-	-	-	-	-	-	-	-	-	-	High	-
5273375	-	+	-	-	0.2038	+	-	-	-	-	-	-	-	-	-	-	-	Low	-
5276097	+	+	-	-	1.0397	-	-	-	-	-	-	-	-	-	-	-	-	High	-
5276122	+	+	-	-	0.2336	+	+	-	-	-	-	-	-	-	-	-	-	High	-
5743088	+	+	-	-	0.2807	+	-	-	-	-	-	-	-	-	-	-	-	Low	-
9959508	+	+	-	-	0.619	+	+	-	-	-	-	-	-	-	-	-	-	High	-
10280893	+	+	-	-	0.3982	+	+	-	-	-	-	-	-	-	-	-	-	High	+
18537979	+	+	-	-	0.427	+	+	-	-	-	-	-	-	-	-	-	-	High	+
20739933	+	+	-	-	0.8745	+	+	-	-	-	-	-	-	-	-	-	-	High	-
23152686	-	+	-	-	-0.0731	+	-	-	-	-	-	-	-	-	-	-	-	Low	-
23152929	+	+	-	-	0.7433	+	-	-	-	-	-	-	-	-	-	-	-	High	-
23152934	+	+	+	-	1.2391	+	+	-	-	-	-	-	-	-	-	-	-	High	+
24054864	+	+	-	-	0.6356	-	-	-	-	-	-	-	-	-	-	-	-	High	-
24163747	+	+	-	-	0.4231	+	+	-	-	-	-	-	-	-	-	-	-	High	-
24967621	+	+	-	-	0.4959	+	-	-	-	-	-	-	-	-	-	-	-	High	-
24999215	-	-	-	-	-0.0142	+	+	-	-	-	-	-	-	-	-	-	-	High	-
25204841	+	+	+	-	0.7521	+	+	-	-	-	-	-	-	-	-	-	-	High	+
25358606	+	+	+	-	1.2873	+	+	-	-	-	-	-	-	-	-	-	-	High	-
39834288	+	+	+	-	1.4452	-	-	-	-	-	-	-	-	-	-	-	-	High	-
42170436	+	+	-	-	0.9813	+	+	-	-	-	-	-	-	-	-	-	-	High	-
42228107	+	+	-	-	0.851	+	+	-	-	-	-	-	-	-	-	-	-	Low	-
44815258	+	+	-	-	0.4878	+	-	-	-	-	-	-	-	-	-	-	-	High	-
44816797	+	+	-	-	0.5363	+	-	-	-	-	-	-	-	-	-	-	-	High	-
58953872	+	+	-	-	0.8745	+	+	-	-	-	-	-	-	-	-	-	-	High	-
58953877	+	+	-	-	0.8745	+	+	-	-	-	-	-	-	-	-	-	-	High	-
59237129	+	+	-	-	0.5357	+	-	-	-	-	-	-	-	-	-	-	-	Low	+
59604390	+	+	+	-	1.4041	+	+	-	-	-	-	-	-	-	-	-	-	High	+
59605198	+	+	+	-	1.2794	+	+	-	-	-	-	-	-	-	-	-	-	High	+
59784249	-	+	-	-	1.2234	+	+	-	-	-	-	-	-	-	-	-	-	High	-
59784414	+	+	-	-	0.7756	+	+	-	-	-	-	-	-	-	-	-	-	High	-
59785246	-	+	-	-	0.4222	+	-	-	-	-	-	-	-	-	-	-	-	High	-
59785406	-	+	-	-	0.6464	+	-	-	-	-	-	-	-	-	-	-	-	High	-
66795702	+	+	-	-	1.0637	+	-	-	-	-	-	-	-	-	-	-	-	High	-




Table 7 Predicted toxicity assessment of selected compounds against IPNV VP1 RdRp

Toxicity profile	490824	3012662	3012705	3274414	5273375	5276097	5276122	5743088	9959508	10280893
Mutagenic <sup>c</sup>	None									
Tumorigenic <sup>a</sup>	None	High	None	None						
RE <sup>b</sup>	None	None	None	Low	None	None	Low	None	None	None
Irritant <sup>a</sup>	None									
HERG inhibition I <sup>b</sup>	Weak									
HERG inhibition II <sup>b</sup>	-	+	-	-	+	-	+	+	+	+
Ames toxicity <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
Carcinogens <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
FT (pLC <sub>50</sub> , mg/L) <sup>b</sup>	High, 1.4493	High, 1.3364	High, 1.289	High, 0.9135	High, 1.2677	High, 1.1508	High, 1.2322	High, 1.174	High, 1.2936	High, 1.3447
TPT (pIGC <sub>50</sub> , µg/L) <sup>b</sup>	High, 0.5062	High, 0.4142	High, 0.4114	High, 0.7454	High, 0.5388	High, 0.6038	High, 0.3967	High, 0.4499	High, 0.5237	High, 0.4871
Honeybee toxicity <sup>b</sup>	Low									
Biodegradation <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
Acute oral toxicity <sup>b</sup>	III									
Carcinogenicity (three-class) <sup>b</sup>	Not required									
RAT (LD <sub>50</sub> , mol/kg) <sup>b</sup>	1.8935	2.3915	2.4206	2.4636	2.4041	2.4488	2.2312	2.4479	2.5923	2.7713
<b>Toxicity profile</b>	<b>18537979</b>	<b>20739933</b>	<b>23152686</b>	<b>23152929</b>	<b>23152934</b>	<b>24054864</b>	<b>24163747</b>	<b>24967621</b>	<b>24999215</b>	<b>25204841</b>
Mutagenic <sup>c</sup>	None	Low	None	None	None	High	High	None	None	None
Tumorigenic <sup>a</sup>	None									
RE <sup>b</sup>	None	None	High	High	High	None	None	None	None	None
Irritant <sup>a</sup>	None	None	None	None	None	Low	None	None	None	None
HERG inhibition I <sup>b</sup>	Weak									
HERG inhibition II <sup>b</sup>	+	-	+	+	+	-	-	-	-	+
Ames toxicity <sup>b</sup>	+	-	-	-	-	-	-	-	-	-
Carcinogens <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
FT (pLC <sub>50</sub> , mg/L) <sup>b</sup>	High, 1.3752	High, 1.4731	High, 1.4335	High, 1.4518	High, 1.2124	High, 0.8885	High, 1.0083	Low, 1.4958	Low, 1.3529	Low, 1.4985
TPT (pIGC <sub>50</sub> , µg/L) <sup>b</sup>	High, 0.4549	High, 0.4749	High, 0.3475	High, 0.3264	High, 0.3721	High, 0.5479	High, 0.4754	High, 0.2529	High, 0.4765	High, 0.5004
Honeybee toxicity <sup>b</sup>	Low									
Biodegradation <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
Acute oral toxicity <sup>b</sup>	III									
Carcinogenicity (three-class) <sup>b</sup>	Not required									
RAT (LD <sub>50</sub> , mol/kg) <sup>b</sup>	2.8529	2.2733	2.2743	2.3865	2.4794	2.2269	2.2662	2.4844	2.6327	2.5284
<b>Toxicity profile</b>	<b>25358606</b>	<b>39834288</b>	<b>42170436</b>	<b>42228107</b>	<b>44815258</b>	<b>44816797</b>	<b>58953872</b>	<b>58953877</b>	<b>59237129</b>	<b>59604390</b>
Mutagenic <sup>c</sup>	None	Low	None	High						
Tumorigenic <sup>a</sup>	None	None	Low	None	None	None	None	None	None	High
RE <sup>b</sup>	None									
Irritant <sup>a</sup>	None									
HERG inhibition I <sup>b</sup>	Weak									
HERG inhibition II <sup>b</sup>	+	+	-	-	+	+	-	-	+	+
Ames toxicity <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
Carcinogens <sup>b</sup>	-	-	-	-	-	-	-	-	-	-

FT (pLC <sub>50</sub> , mg/L) <sup>b</sup>	High, 1.1439	High, 1.4429	High, 1.1606	High, 1.4331	High, 1.4499	High, 1.3925	High, 1.4731	High, 1.4731	Low, 1.9838	High, 1.2676
TPT (pIGC <sub>50</sub> , µg/L) <sup>b</sup>	High, 0.4812	High, 0.5824	High, 0.6336	High, 0.4559	High, 0.3785	High, 0.5532	High, 0.4749	High, 0.4749	High, 0.6335	High, 0.3239
Honeybee toxicity <sup>b</sup>	Low									
Biodegradation <sup>b</sup>	-	III	-	III	III	-	-	-	-	-
Acute oral toxicity <sup>b</sup>	III									
Carcinogenicity (three-class) <sup>b</sup>	Not required									
RAT (LD <sub>50</sub> , mol/kg) <sup>b</sup>	2.2596	2.2023	2.3668	2.3296	2.2836	2.321	2.2733	2.2733	2.4571	2.5247
<b>Toxicity profile</b>	<b>59605198</b>	<b>59784249</b>	<b>59784414</b>	<b>59785246</b>	<b>59785406</b>	<b>66795702</b>	<b>70114340</b>	<b>69978228</b>	<b>71194466</b>	<b>71452538</b>
Mutagenic <sup>c</sup>	High	None								
Tumorigenic <sup>a</sup>	High	None								
RE <sup>c</sup>	None	None	None	None	None	High	None	None	None	None
Irritant <sup>a</sup>	None									
HERG inhibition I <sup>b</sup>	Weak									
HERG inhibition II <sup>b</sup>	+	-	+	+	+	+	-	+	+	+
Ames toxicity <sup>b</sup>	-	+	-	-	-	-	-	-	-	-
Carcinogens <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
FT (pLC <sub>50</sub> , mg/L) <sup>b</sup>	High, 1.1918	High, 0.9868	High, 0.965	High, 1.1446	High, 1.1335	High, 1.4583	Low, 1.3099	Low, 1.3099	High, 1.5963	Low, 1.4317
TPT (pIGC <sub>50</sub> , µg/L) <sup>b</sup>	High, 0.5055	High, 0.622	High, 0.4835	High, 0.4416	High, 0.4223	High, 0.3263	High, 0.4834	High, 0.4834	High, 0.3216	High, 0.3877
Honeybee toxicity <sup>b</sup>	Low									
Biodegradation <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
Acute oral toxicity <sup>b</sup>	III									
Carcinogenicity (three-class) <sup>b</sup>	Not required									
RAT (LD <sub>50</sub> , mol/kg) <sup>b</sup>	2.6089	2.6679	2.6756	2.6682	2.6564	2.4875	2.5076	2.5428	2.3759	2.7741
<b>Toxicity profile</b>	<b>71452539</b>	<b>71456057</b>	<b>71457852</b>	<b>71457853</b>	<b>71461490</b>	<b>71463215</b>	<b>74318036</b>	<b>72561223</b>	<b>76259895</b>	<b>77236156</b>
Mutagenic <sup>c</sup>	None									
Tumorigenic <sup>a</sup>	None									
RE <sup>c</sup>	None									
Irritant <sup>a</sup>	None									
HERG inhibition I <sup>b</sup>	Weak									
HERG inhibition II <sup>b</sup>	+	+	+	-	+	-	+	+	-	+
Ames toxicity <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
Carcinogens <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
FT (pLC <sub>50</sub> , mg/L) <sup>b</sup>	Low, 1.6115	Low, 1.6589	High, 1.3639	High, 1.246	Low, 1.7366	Low, 1.5449	High, 1.1057	High, 1.329	High, 1.3351	High, 1.4949
TPT (pIGC <sub>50</sub> , µg/L) <sup>b</sup>	High, 0.3166	High, 0.2518	High, 0.4052	High, 0.3028	High, 0.2401	High, 0.234	High, 0.5002	High, 0.5396	High, 0.4232	High, 0.5486
Honeybee toxicity <sup>b</sup>	Low									
Biodegradation <sup>b</sup>	-	-	-	-	-	-	-	-	-	-
Acute oral toxicity <sup>b</sup>	III									
Carcinogenicity (three-class) <sup>b</sup>	Not required									
RAT (LD <sub>50</sub> , mol/kg) <sup>b</sup>	2.4763	2.601	2.686	2.5399	2.6534	2.5176	2.6378	2.4561	2.4322	2.4325

**Notes:** Toxicity data was expressed as the negative logarithm of 50% growth inhibitory concentration (pIGC<sub>50</sub>). The value of LD<sub>50</sub> for a substance is the dose required to kill half the members of a tested population after a specified test duration. Compound names from PubChem. <sup>a</sup>Calculated using DataWarrior<sup>41</sup> version 4.7.2; <sup>b</sup>calculated using <http://lmmd.ecust.edu.cn:8000/predict/site-6>.

**Abbreviations:** IPNV, infectious pancreatic necrosis virus; RdRp, RNA-dependent RNA polymerase; RE, reproductive effectiveness; FT, fish toxicity; LC<sub>50</sub>, lethal concentration at 50%; TPT, *Tetrahymena pyriformis* toxicity; RAT, rat acute toxicity.



**Figure 4** Viability of CHSE cells after treatment with PubChem 3274414 and 39834288 compounds.

**Notes:** CHSE monolayers were treated with increasing concentrations of 3274414 and 39834288 compounds dissolved in DMSO and DMSO:acetone (1:1), respectively; and equivalent amounts of the corresponding solvents (0.5 µL/well), for 24 hours at 14°C before performing the MTT assay. Cell viability is shown as the percentage relative to non-treated cells, taken as an average ( $\pm$  SD) from three independent experiments performed in triplicate.


**Abbreviation:** DMSO, dimethyl sulfoxide.

## Determination of anti-IPNV activity induced by selected compounds

Infected CHSE cells were further incubated with different concentrations of selected compounds (3274414 or 39834288) for 24 hours. Viral loads were subsequently measured as the total abundance of viral transcripts quantified by RT-qPCR. As shown in Figure 5, different inhibition patterns were observed dependent on the compound and IPNV strain used. When the compounds induced antiviral activity, this occurred in a dose-dependent manner.

For the 3274414 compound, both IPNV strains were inhibited following a similar pattern. At the maximum concentration tested (50 µM), the infectivity of both viral strains was reduced by approximately 50% (Figure 5A). The potency of this compound was lower than that induced by mycophenolic acid or ribavirin,<sup>48</sup> which at 1 µM both inhibited the infectivity of IPNV Sp up to 90%. Our docking data showed that 3274414–polymerase interactions were only hydrophobic and involved residues Lys554, Ala555, Glu557, and Asn580. The compound showed the same orientation in its binding to the polymerase in all three IPNV strains.

For the 39834288 compound, its antiviral capacity was markedly different (Figure 5B), exhibiting no effect upon the Sp strain. In contrast, its potency was found to be greater than that of compound 3274414 against the LWVRT60 strain, reducing its infectivity by 80% at 20 µM. By adjusting



**Figure 5** Percentage of inhibition of infectivity of both IPNV Sp and LWVRT60 strains after treatment with PubChem 3274414 or 39834288 compound.

**Notes:** CHSE monolayers infected with 0.01 TCID<sub>50</sub>/mL of either IPNV Sp or IPNV LWVRT60 were treated after viral adsorption with increasing concentrations (1, 5, 10, 20, and 50 µM) of either PubChem 3274414 or 39834288 compounds. After 24 hours, the amount of replicating virus was determined by RT-qPCR. Results are presented as percentage inhibition of infection produced by compounds (inhibitor) in comparison to corresponding organic solvent controls (vehicle), shown as the average ( $\pm$ SD) from four independent experiments. Dashed lines are the fit to a dose–response curve  $\% \text{ IPNV inhibition} = \text{Bottom} + (\text{Top}-\text{Bottom}) / (1 + (\text{IC}_{50} / [\text{inhibitor}])^{\text{Hill}_{\text{slope}}})$  with a Hill slope of 1.

**Abbreviations:** IPNV, infectious pancreatic necrosis virus; TCID<sub>50</sub>, 50% tissue-culture infective dose; RT-qPCR, reverse-transcription quantitative polymerase chain reaction.

the parameters to a Hill equation, an IC<sub>50</sub> of 3.1 µM was calculated. The estimated IC<sub>50</sub> value for compound 3274414 was about 15 µM for both Sp and LWVRT60 strains. These IC<sub>50</sub> values are comparable with those of other nonnucleoside inhibitors designed to block the RNA-template tunnel of RdRp dengue virus 2.<sup>51</sup> The compounds (NITD1, -2, and -29) analyzed therein showed no toxicity up to 50 µM and presented IC<sub>50</sub> values of 7.2, 0.7, and 1.5 µM, respectively. In spite of showing inhibitory activity against the recombinant viral polymerase, the antiviral activity of NITD1 and NITD2 compounds in cell cultures could not be


demonstrated.<sup>51</sup> Selective inhibition of one virus subtype over other subtypes has been previously for small-molecule inhibitors of influenza A virus, although the molecular basis of such specificity remained obscure.<sup>52</sup>

The interactions of 39834288–polymerase (H-bonds between the compound and the residues Pro552, Glu557, and, Asn623) predicted by molecular docking were similar for the three IPNV strains (Figure 6A). Therefore, the question remained as to how compound 39834288 showed no activity against the Sp strain. The calculation of position for the compounds docked to the cavity in the surface of the thumb was made in the absence of residues 31–36 and 122–157. Therefore, it is understandable that they did not show differences in 39834288–polymerase interactions. However, cell-culture assays for antiviral activity were carried out with the full enzyme. Binding of the inhibitor in the cavity is only possible if the loop 122–157 is displaced, especially for the compound 39834288, which would have large clashes (Figure 6B), as it is located in the full protein (2YI8). As would be expected, based upon 3274414–polymerase docking-calculated interactions, a much smaller rearrangement of loop 122–157 would be required to accommodate compound 39834288. In this sense, the binding energy of loop 122–157 to the domain that forms the cavity

(residues Asp523 to Asp691) was calculated using FoldX software.<sup>39</sup> These data showed that although there were neither differences between the three strains for the numbers of hydrogen-bonds (Asp124–Ala588, Thr146–Asn624, Tyr159–Glu594, Asp124–Arg612, Asp124–Tyr613, Thr146–Asn624, Gln149–Asn580, and Ile154–Tyr589), saline bridges (Asp124–Arg612) nor the interface area (about 1,060 Å<sup>2</sup>), there were appreciable differences in the global calculation of binding free-energy variation. The calculated  $\Delta G$  for the binding of both domains was  $-36.9$  kcal/mol for the LWVRT60 strain and  $-38.1$  kcal/mol for the Sp strain. In other words, the rearrangement of loop 122–155 was more energy-expensive for the polymerase of the Sp strain than for LWVRT60. Such may also explain the observed inability of compound 39834288 to displace this loop in the Sp strain, resulting in negligible activity of its polymerase and in turn its infectivity.

## Conclusion

The results presented herein are compatible with the existence of an allosteric regulation site in the IPNV VP1 polymerase. From a library of 23,760 compounds, nine and 50 were predicted as antiviral drug candidates against HCV and IPNV polymerases, respectively (Figure 7). Two nontoxic




**Figure 6** Structural details of docked compounds on cavity.

**Notes:** (A) Electrostatic surface potential without (empty cavity) and with the best-docked PubChem 3274414 and 39834288 compounds in IPNV Jasper (2YI8), Sp (homology model), and LWVRT60 (homology model) strains. (B) Clashes of docked 3274414 (upper) and 39834288 (lower) compounds with the IPNV VP1 Sp strain with the amino-acid sequence 122–157 depicted in red.

**Abbreviation:** IPNV, infectious pancreatic necrosis virus.

## Structure-based virtual screening



**Figure 7** Schematic workflow for the hit-compound selection.

**Notes:** Virtual screening workflow and procedure used for selecting hits whose bioactivity was experimentally tested. The number of compounds that passed each step are shown. From an initial set of 23,764 compounds, 50 compounds were identified as putative VP1 IPNV RdRp inhibitors (first and second filters). Two of the 50 compounds were selected for proof-of-concept assessment by in vitro testing.

**Abbreviations:** IPNV, infectious pancreatic necrosis virus; RdRp, RNA-dependent RNA polymerase; HCV, hepatitis C virus; ADMET, absorption, distribution, metabolism, excretion, and toxicity; LogP, logarithm of partition coefficient; LogS, logarithm of solubility; Ro5, rule of five; HBA, hydrogen-bond acceptor; HBD, hydrogen-bond donor.

compounds were tested in vitro, and showed antiviral activity against IPNV in the low-micromolar range.

## Acknowledgments

Special thanks are due to Dr Amparo Estepa Perez, who has passed away, but contributed to financing this work. MBP is financed by the Generalidad Valenciana, fellowship ACIF/2016. We are grateful to Research, Technological Innovation, and the Supercomputing Center of Extremadura

(CénitS) for allowing us to use their supercomputing facilities (Lusitania II). This work was supported by the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad project AGL2014-51773-C3-1-R of the Ministerio de Economía y Competitividad of Spain. We thank Dr Beatriz Novoa (Instituto de Investigaciones Marinas, Consejo Superior de Investigaciones Científicas, Vigo, Spain) for providing the IPNV LWVRT60 strain. Technical support from Angeles Gómez is also acknowledged.

Dr Matthew Mold (Keele University, Newcastle, UK) provided some assistance with the English. We thank the anonymous reviewers for their constructive comments, which helped us to improve the manuscript.

## Author contributions

JAE, LP, and AF conceived and designed the experiments and wrote the paper, MBP, JC, and AF conducted the in vitro experiments, JAE and VG conducted the in silico molecular docking experiments and the DrugBank analysis, and LP and JAE were responsible for funding acquisition. All authors contributed to the general discussion of the manuscript. All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- de Clercq E. Antivirals: current state of the art. *Future Virol.* 2008; 3(4):393–405.
- Griffiths PD. A perspective on antiviral resistance. *J Clin Virol.* 2009; 46(1):3–8.
- Awoonor-Williams E, Walsh AG, Rowley CN. Modeling covalent-modifier drugs. *Biochim Biophys Acta.* 2017;1865(11 Pt B): 1664–1675.
- Raghavendra NM, Pingili D, Kadasi S, Mettu A, Prasad S. Dual or multi-targeting inhibitors: the next generation anticancer agents. *Eur J Med Chem.* 2018;143:1277–1300.
- Wolf K, Snieszko SF, Dunbar CE, Pyle E. Virus nature of infectious pancreatic necrosis in trout. *Proc Soc Exp Biol Med.* 1960;104:105–108.
- Munro ES, Midtlyng PJ. Infectious pancreatic necrosis and associated aquatic birnaviruses. In: Woo P, Bruno D, editors. *Fish Diseases and Disorders*. 2nd ed. Wallingford, UK: CABI; 2011:1–65.
- Guy DR, Bishop SC, Brotherstone S, et al. Analysis of the incidence of infectious pancreatic necrosis mortality in pedigree Atlantic salmon, *Salmo salar* L., populations. *J Fish Dis.* 2006;29(11):637–647.
- Rønneseth A, Wergeland HI, Devik M, Evensen O, Pettersen EF. Mortality after IPNV challenge of Atlantic salmon (*Salmo salar* L.) differs based on developmental stage of fish or challenge route. *Aquaculture.* 2007;271(1–4):100–111.
- Dhar A, LaPatra S, Orry A, Allnut F. Infectious pancreatic necrosis virus. In: Woo P, Cipriano R, editors. *Fish Viruses and Bacteria: Pathobiology and Protection*. Wallingford, UK: CABI; 2017:1–12.
- Delmas B, Mundt E, Vakharia VN, Wu JL. Family – Birnaviridae. In: King AM, Carstens EB, editors. *Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses*. London: Academic Press; 2012:499–507.
- Lvov DK, Shchelkanov MY, Alkhovskiy SV, Deryabin PG. Double-stranded RNA viruses. In: Lvov DK, Shchelkanov MY, Vladimirovich S, Alkhovskiy SV, Deryabin PG, editors. *Zoonotic Viruses in Northern Eurasia: Taxonomy and Ecology*. Boston: Academic Press; 2015: 113–133.
- Büyükekiz AG, Altun S, Hansen EF, et al. Infectious pancreatic necrosis virus (IPNV) serotype Sp is prevalent in Turkish rainbow trout farms. *J Fish Dis.* 2018;41(1):95–104.
- Holopainen R, Eriksson-Kallio AM, Gadd T. Molecular characterisation of infectious pancreatic necrosis viruses isolated from farmed fish in Finland. *Arch Virol.* 2017;162(11):3459–3471.
- Manríquez RA, Vera T, Villalba MV, et al. Molecular characterization of infectious pancreatic necrosis virus strains isolated from the three types of salmonids farmed in Chile. *Virol J.* 2017;14(1):17.
- Ogut H, Altuntas C, Parlak R. Viral surveillance of cultured rainbow trout in the eastern Black Sea, Turkey. *J Aquat Anim Health.* 2013;25(1): 27–35.
- Ruane NM, McCarthy LJ, Swords D, Henshilwood K. Molecular differentiation of infectious pancreatic necrosis virus isolates from farmed and wild salmonids in Ireland. *J Fish Dis.* 2009;32(12):979–987.
- Wallace IS, McKay P, Murray AG. A historical review of the key bacterial and viral pathogens of Scottish wild fish. *J Fish Dis.* 2017;40(12): 1741–1756.
- Crane MS, Hardy-Smith P, Williams LM, et al. First isolation of an aquatic birnavirus from farmed and wild fish species in Australia. *Dis Aquat Organ.* 2000;43(1):1–14.
- Moreno P, Oliveira JG, Labella A, et al. Surveillance of viruses in wild fish populations in areas around the Gulf of Cadiz (South Atlantic Iberian Peninsula). *Appl Environ Microbiol.* 2014;80(20):6560–6571.
- Delmas B, Mundt E, Vakharia V, Wu J. Family Birnaviridae. In: King AM, Carstens EB, editors. *Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses*. London: Academic Press; 2012:499–507.
- Molloy SD, Pietrak MR, Bricknell I, Bouchard DA. Experimental transmission of infectious pancreatic necrosis virus from the blue mussel, *Mytilus edulis*, to cohabitating Atlantic salmon (*Salmo salar*) smolts. *Appl Environ Microbiol.* 2013;79(19):5882–5890.
- Munro ES, Gahlawat SK, Acosta F, Ellis AE. In infectious pancreatic necrosis virus carrier Atlantic salmon, *Salmo salar* L., post-smolts, almost all kidney macrophages ex vivo contain a low level of non-replicating virus. *J Fish Dis.* 2006;29(1):43–48.
- Chevalier C, Lepault J, Erk I, da Costa B, Delmas B. The maturation process of pVP2 requires assembly of infectious bursal disease virus capsids. *J Virol.* 2002;76(5):2384–2392.
- Santi N, Song H, Vakharia VN, Evensen O. Infectious pancreatic necrosis virus VP5 is dispensable for virulence and persistence. *J Virol.* 2005;79(14):9206–9216.
- Magyar G, Chung HK, Dobos P. Conversion of VP1 to VPg in cells infected by infectious pancreatic necrosis virus. *Virology.* 1998;245(1): 142–150.
- Duncan R, Mason CL, Nagy E, Leong JA, Dobos P. Sequence analysis of infectious pancreatic necrosis virus genome segment B and its encoded VP1 protein: a putative RNA-dependent RNA polymerase lacking the Gly-Asp-Asp motif. *Virology.* 1991;181(2):541–552.
- Koonin EV, Wolf YI, Nagasaki K, Dolja VV. The Big Bang of picorna-like virus evolution antedates the radiation of eukaryotic supergroups. *Nat Rev Microbiol.* 2008;6(12):925–939.
- Dobos P. In vitro guanylation of infectious pancreatic necrosis virus polypeptide VP1. *Virology.* 1993;193(1):403–413.
- Di Marco S, Volpari C, Tomei L, et al. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. *J Biol Chem.* 2005;280(33): 29765–29770.
- Graham SC, Sarin LP, Bahar MW, et al. The N-terminus of the RNA polymerase from infectious pancreatic necrosis virus is the determinant of genome attachment. *PLoS Pathog.* 2011;7(6):e1002085.
- Bahar MW, Sarin LP, Graham SC, et al. Structure of a VP1-VP3 complex suggests how birnaviruses package the VP1 polymerase. *J Virol.* 2013;87(6):3229–3236.
- Biasini M, Bienert S, Waterhouse A, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic Acids Res.* 2014;42:W252–W258.
- Altschul SF, Madden TL, Schäffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* 1997;25(17):3389–3402.
- Remmert M, Biegert A, Hauser A, Söding J. HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment. *Nat Methods.* 2011;9(2):173–175.

35. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. *Electrophoresis*. 1997; 18(15):2714–2723.
36. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol*. 1993;234(3):779–815.
37. Encinar JA, Fernández-Ballester G, Galiano-Ibarra V, Micol V. In silico approach for the discovery of new PPAR $\gamma$  modulators among plant-derived polyphenols. *Drug Des Devel Ther*. 2015;9:5877–5895.
38. Galiano V, Garcia-Valtanan P, Micol V, Encinar JA. Looking for inhibitors of the dengue virus NS5 RNA-dependent RNA-polymerase using a molecular docking approach. *Drug Des Devel Ther*. 2016;10: 3163–3181.
39. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. *Nucleic Acids Res*. 2005;33: W382–W388.
40. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem*. 2010;31(2):455–461.
41. Sander T, Freyss J, von Korff M, Rufener C. DataWarrior: an open-source program for chemistry aware data visualization and analysis. *J Chem Inf Model*. 2015;55(2):460–473.
42. Cheng F, Li W, Zhou Y, et al. AdmetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. *J Chem Inf Model*. 2012;52(11):3099–3105.
43. Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. *Nucleic Acids Res*. 2014;42:D1091–D1097.
44. Reed LJ, Muench H. A Simple method of estimating fifty per cent endpoints. *Am J Epidemiol*. 1938;27(3):493–497.
45. Falco A, Chico V, Marroquí L, Perez L, Coll JM, Estepa A. Expression and antiviral activity of a beta-defensin-like peptide identified in the rainbow trout (*Oncorhynchus mykiss*) EST sequences. *Mol Immunol*. 2008;45(3): 757–765.
46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C_t}$  method. *Methods*. 2001; 25(4):402–408.
47. Sobhkhez M, Joensen LL, Tollersrud LG, Strandskog G, Thim HL, Jørgensen JB. A conserved inhibitory role of suppressor of cytokine signaling 1 (SOCS1) in salmon antiviral immunity. *Dev Comp Immunol*. 2017;67:66–76.
48. Marroquí L, Estepa A, Perez L. Inhibitory effect of mycophenolic acid on the replication of infectious pancreatic necrosis virus and viral hemorrhagic septicemia virus. *Antiviral Res*. 2008;80(3):332–338.
49. García I, Galiana A, Falcó A, Estepa A, Perez L. Characterization of an infectious pancreatic necrosis (IPN) virus carrier cell culture with resistance to superinfection with heterologous viruses. *Vet Microbiol*. 2011; 149(1–2):48–55.
50. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev*. 2001;46(1–3):3–26.
51. Niyomrattanakit P, Chen YL, Dong H, et al. Inhibition of dengue virus polymerase by blocking of the RNA tunnel. *J Virol*. 2010;84(11): 5678–5686.
52. Yuan S, Chu H, Ye J, et al. Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface. *Antiviral Res*. 2017;137:58–66.

## Supplementary material





Figure S1 (Continued)



**Figure S1** Molecular structure of compounds selected against the allosteric binding site for HCV NS5B (A) and IPNV VP1 RdRp (B).

**Note:** Cluster number and PubChem ID indicated for each compound.

**Abbreviations:** HCV, hepatitis C virus; IPNV, infectious pancreatic necrosis virus; RdRp, RNA-dependent RNA polymerase.

### Drug Design, Development and Therapy

Dovepress

### Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>